Virus tracking study aims to protect transplant patients from cancer risk
NCT ID NCT04189835
Summary
This study followed 509 kidney transplant patients to understand how monitoring Epstein-Barr virus (EBV) levels might help predict serious risks. Researchers tracked patients' blood for persistent EBV infection to see if it signaled a higher chance of developing certain cancers, severe infections requiring hospital stays, or death. The goal was to gather evidence to help doctors better manage immune-suppressing medications after transplantation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Central Region Denmark, Denmark
-
Odense University Hospital
Odense, Region Syddanmark, Denmark
-
Rikshospitalet, Oslo Universitetssykehus
Oslo, Norway
Conditions
Explore the condition pages connected to this study.